Range Low Price High Price Comment
30 days $14.59 $16.25 Monday, 29th Apr 2024 CPRX stock ended at $15.23. This is 2.28% more than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 2.07% from a day low at $14.98 to a day high of $15.29.
90 days $13.12 $17.50
52 weeks $11.09 $17.77

Historical Catalyst Pharmaceuticals prices

Date Open High Low Close Volume
Feb 01, 2016 $1.83 $1.97 $1.81 $1.92 334 800
Jan 29, 2016 $1.85 $1.98 $1.85 $1.86 557 800
Jan 28, 2016 $1.97 $1.97 $1.83 $1.85 411 600
Jan 27, 2016 $2.02 $2.06 $1.95 $1.96 332 000
Jan 26, 2016 $2.08 $2.11 $1.98 $2.04 274 900
Jan 25, 2016 $2.08 $2.15 $2.07 $2.08 512 900
Jan 22, 2016 $2.21 $2.25 $2.09 $2.10 434 900
Jan 21, 2016 $2.16 $2.21 $2.09 $2.16 351 200
Jan 20, 2016 $2.02 $2.21 $1.93 $2.18 585 500
Jan 19, 2016 $2.12 $2.18 $1.99 $2.07 670 500
Jan 15, 2016 $2.07 $2.13 $2.01 $2.10 781 900
Jan 14, 2016 $2.01 $2.22 $1.88 $2.18 988 400
Jan 13, 2016 $1.95 $2.22 $1.95 $2.01 1 524 400
Jan 12, 2016 $1.90 $2.03 $1.86 $1.95 565 600
Jan 11, 2016 $1.90 $1.90 $1.77 $1.88 490 800
Jan 08, 2016 $2.07 $2.09 $1.81 $1.90 709 500
Jan 07, 2016 $2.13 $2.14 $1.92 $2.00 553 300
Jan 06, 2016 $2.33 $2.33 $2.17 $2.20 504 700
Jan 05, 2016 $2.33 $2.42 $2.30 $2.36 247 000
Click to get the best stock tips daily for free!

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT